Dowsett M, Murray R M, Pitt P, Jeffcoate S L
Eur J Cancer Clin Oncol. 1985 Sep;21(9):1063-8. doi: 10.1016/0277-5379(85)90292-5.
The response rate of advanced postmenopausal breast cancer patients to treatment with aminoglutethimide (AG) + danazol was significantly worse than that with AG alone. The suppression of serum oestradiol levels by AG + danazol was similar to that by AG alone, but the combination treatment also suppressed sex hormone binding globulin (SHBG) levels and increased the % free oestradiol, whilst these parameters were unaffected by AG alone. The degree of suppression by AG + danazol of free oestradiol concentrations was less than the suppression of total oestradiol level and in some patients the concentration of the free fraction was increased above pretreatment levels. These effects on the presumed biologically active unbound fraction of oestradiol may explain the poor clinical response rate to AG + danazol.
绝经后晚期乳腺癌患者接受氨鲁米特（AG）+达那唑治疗的缓解率明显低于单独使用AG治疗的缓解率。AG+达那唑对血清雌二醇水平的抑制作用与单独使用AG相似，但联合治疗还会抑制性激素结合球蛋白（SHBG）水平并增加游离雌二醇百分比，而这些参数不受单独使用AG的影响。AG+达那唑对游离雌二醇浓度的抑制程度小于对总雌二醇水平的抑制程度，在一些患者中，游离部分的浓度高于治疗前水平。这些对推测具有生物活性的未结合雌二醇部分的影响可能解释了对AG+达那唑临床缓解率不佳的原因。
